Brown E, Wilding JPH, Barber TM, Alam U, Cuthbertson DJ (2019) Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: mechanistic possibilities
When you look at the prevalence of obesity, diabetes and related metabolic conditions in the U.S., its clear that GLP-1 medications are not a niche solution
According to recent surveys from late 2025, approximately 12 percent of American adults have used GLP-1 medications such as Ozempic or Wegovy
PMID: 26 BrandNRQuLGChaoAIlbawiAM
You've got the framework for setting up a diet plan thats primed to work with your weight loss meds
However, we recommend patch testing on a small area first - as with any new scalp product